Previous Close | 36.77 |
Open | 36.33 |
Bid | 0.00 x 1200 |
Ask | 0.00 x 1000 |
Day's Range | 35.34 - 36.88 |
52 Week Range | 20.33 - 59.03 |
Volume | 321,654 |
Avg. Volume | 514,791 |
Market Cap | 1.689B |
Beta (5Y Monthly) | 1.05 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.58 |
Earnings Date | May 05, 2021 - May 10, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 56.63 |
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2020 and provided a summary of recent business and clinical highlights.
Hijacking the immune system to destroy cancer with bispecific antibodies could be a lucrative business for biotech stocks like Amgen, Genmab and Regeneron Pharmaceuticals.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will participate in five upcoming virtual investor conferences.